ImmunoTargets and Therapy

Scope & Guideline

Championing Open Access to Immunology Insights

Introduction

Delve into the academic richness of ImmunoTargets and Therapy with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN-
PublisherDOVE MEDICAL PRESS LTD
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationIMMUNOTARGETS THER / IMMUNOTARGETS THER.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressPO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND

Aims and Scopes

The journal 'ImmunoTargets and Therapy' is dedicated to advancing the field of immunology through the exploration of therapeutic targets and strategies. It provides a platform for innovative research that contributes to the understanding and treatment of immune-related diseases, cancer immunotherapy, and autoimmune disorders.
  1. Immunotherapy and Cancer Treatment:
    The journal focuses extensively on various immunotherapeutic approaches, including immune checkpoint inhibitors, CAR-T cell therapies, and novel immunotherapies for different types of cancers such as non-small cell lung cancer, hepatocellular carcinoma, and multiple myeloma.
  2. Autoimmunity and Inflammatory Diseases:
    Research on the pathophysiology and treatment strategies for autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, and eosinophilic esophagitis, is a significant scope of the journal.
  3. Infectious Diseases and Immune Response:
    The journal publishes studies on the immune response to infectious diseases, including tuberculosis and viral infections, highlighting the role of immune targets in treatment and prevention.
  4. Emerging Biomarkers and Therapeutic Targets:
    The identification and characterization of biomarkers and therapeutic targets across various diseases are central to the journal's mission, providing insights into personalized medicine and targeted therapies.
  5. Research Methodologies in Immunology:
    The journal supports diverse research methodologies, including clinical trials, retrospective studies, single-cell transcriptomics, and bioinformatics, to advance the understanding of immune mechanisms and therapeutic strategies.
The journal 'ImmunoTargets and Therapy' has identified several trending and emerging themes that reflect the latest advancements and interests in the field of immunology and therapeutic interventions.
  1. Combination Therapies in Cancer Treatment:
    There is a growing trend towards exploring combination therapies, particularly those involving immune checkpoint inhibitors and targeted therapies, which are increasingly recognized for their potential to enhance treatment efficacy.
  2. Personalized Medicine and Biomarker Discovery:
    Emerging themes include the identification of biomarkers that can predict treatment response, facilitating a move towards personalized medicine in immunotherapy, particularly in oncology.
  3. Research on the Microbiome and Immune Interactions:
    Studies exploring the relationship between the microbiome and immune responses are gaining traction, indicating a new frontier in understanding how microbiota can influence immunotherapy outcomes.
  4. Innovative Approaches to Autoimmune Diseases:
    The journal is increasingly publishing research on novel approaches to treating autoimmune diseases, including the use of biologics and targeted therapies that address specific immune pathways.
  5. Advances in Gene Therapy and Immune Modulation:
    Gene therapy strategies, particularly those aimed at immune modulation, are emerging as a significant focus, reflecting advancements in genetic engineering and its applications in immunotherapy.

Declining or Waning

While 'ImmunoTargets and Therapy' continues to evolve, certain themes have shown a decline in frequency and focus over recent years, indicating a shift in research priorities within the field.
  1. Traditional Pharmacotherapy for Autoimmune Diseases:
    There is a noticeable decrease in publications focusing solely on traditional pharmacological treatments for autoimmune diseases, as the field shifts towards more innovative immunotherapy approaches.
  2. Basic Immunology without Therapeutic Context:
    The journal has seen a decline in studies that address basic immunological concepts without direct application to therapeutic interventions, reflecting a preference for research that links basic science to clinical outcomes.
  3. Generalized Discussions on Allergies:
    Research related to generalized allergy discussions, such as those not tied to specific therapeutic targets or novel treatments, appears to be waning, as the focus has shifted towards targeted immunotherapies.
  4. Longitudinal Studies in Rare Diseases:
    There is a reduced emphasis on longitudinal studies in rare autoimmune diseases, as the journal seems to prioritize studies with broader implications or more common conditions.
  5. Generic Reviews of Established Treatments:
    The frequency of generic reviews on established treatments without new insights or advances has decreased, as the journal encourages more innovative and research-driven articles.

Similar Journals

Journal of Immunology Research

Empowering Research: Your Source for Cutting-Edge Immunology Insights
Publisher: HINDAWI LTDISSN: 2314-8861Frequency:

Journal of Immunology Research, published by HINDAWI LTD, stands as a pivotal open-access journal in the realm of immunology, with a particular emphasis on advancing knowledge in both fundamental and applied aspects of the field. Since its inception in 1990, the journal has committed to the dissemination of high-quality research, earning a respectable impact factor that reflects its significance. Based in Egypt, it provides a platform for researchers from around the world, showcasing innovative studies and reviews that contribute to the understanding of immune system mechanisms. Its 2023 rankings place it in the Q2 category for Immunology and Allergy, and Q1 in the broader category of Medicine (miscellaneous), indicating a strong reputation among its peers. Through its open-access model, the journal promotes wide accessibility of cutting-edge research, catering to researchers, professionals, and students alike. With ambitions that converge through 2024, the Journal of Immunology Research continues to be an essential resource for those seeking to explore the forefront of immunological science.

SEMINARS IN IMMUNOLOGY

Transforming Knowledge into Immunological Innovation
Publisher: ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTDISSN: 1044-5323Frequency: 6 issues/year

SEMINARS IN IMMUNOLOGY, published by Academic Press Ltd - Elsevier Science Ltd, stands as a leading journal in the field of immunology and allergy, with an impressive impact factor that reflects its significant contribution to advancing research and discourse within these vital areas of medical science. Established in 1989, this esteemed journal has garnered a reputation for disseminating high-quality, peer-reviewed articles that span a broad spectrum of immunological topics, making it an essential resource for researchers, healthcare professionals, and students alike. Currently ranked Q1 in both Immunology and Allergy categories, SEMINARS IN IMMUNOLOGY ranks 39th among 233 journals in Immunology and Allergy and 43rd among 236 in Immunology and Microbiology according to Scopus, placing it in the 83rd and 81st percentiles respectively. This underscores its pivotal role in shaping the future of immunological research and clinical practices. While the journal operates under a subscription model with no open access option, it remains committed to providing comprehensive insights and fostering scholarly collaboration within the global immunology community.

JOURNAL OF EXPERIMENTAL MEDICINE

Innovating Solutions for Tomorrow's Health Challenges
Publisher: ROCKEFELLER UNIV PRESSISSN: 0022-1007Frequency: 12 issues/year

JOURNAL OF EXPERIMENTAL MEDICINE, published by Rockefeller University Press, is a renowned peer-reviewed journal dedicated to advancing the field of experimental medicine since its inception in 1896. With an impressive impact factor and categorized in the Q1 quartile for Immunology, Immunology and Allergy, and Miscellaneous Medicine, this journal stands at the forefront of medical research and innovation. It provides a prestigious platform for scholars and practitioners to disseminate groundbreaking findings that drive the understanding of disease mechanisms and therapeutic strategies. While the journal is not open access, it maintains high visibility and engagement within the scientific community, fostering collaboration among researchers, professionals, and students alike. The journal's consistent ranking in the top percentiles of Scopus illustrates its significant impact and commitment to excellence in medical research.

HUMAN IMMUNOLOGY

Navigating the Landscape of Immunological Science
Publisher: ELSEVIER SCIENCE INCISSN: 0198-8859Frequency: 12 issues/year

HUMAN IMMUNOLOGY, published by Elsevier Science Inc, serves as a critical platform for disseminating research in the fields of immunology and allergy, as well as various aspects of miscellaneous medicine since its inception in 1980. With an ISSN of 0198-8859 and E-ISSN 1879-1166, this journal is pivotal for researchers and practitioners looking to advance their understanding of human immune responses and related conditions. The journal currently holds a respectable position within its field, as highlighted by its 2023 Scopus ranks—#114/233 in Immunology and Allergy and #132/236 in Immunology and Microbiology. Moreover, it maintains a Q2 quartile ranking in both Immunology and Allergy and miscellaneous Medicine, underscoring its influence and reach within the scientific community. Although it does not currently offer Open Access options, HUMAN IMMUNOLOGY remains dedicated to providing valuable insights and fostering academic discourse within its discipline, characterized by a rigorous peer-review process and a focus on innovative research trajectories.

Cancer Immunology Research

Unraveling the Immune Response in Cancer
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2326-6066Frequency: 12 issues/year

Cancer Immunology Research is a leading journal dedicated to the rapidly evolving field of cancer immunology, published by the American Association for Cancer Research. Established in 2013, this prestigious journal has quickly made a significant impact in its domain, achieving a 2023 Q1 ranking in both Cancer Research and Immunology. With an impressive Scopus rank of 24 out of 230 in cancer research and 28 out of 236 in immunology, it occupies a valuable position for researchers, professionals, and students engaged in cutting-edge cancer studies. Although it does not offer open access, the journal is committed to disseminating high-quality, peer-reviewed research that advances our understanding of the immune system’s role in cancer. The journal's objectives include fostering innovative studies, enhancing collaboration across disciplines, and promoting the translation of research findings into clinical applications, making it a vital resource for anyone invested in cancer therapy and immunological research.

ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS

Championing Discoveries in Immunology Since 1954
Publisher: DE GRUYTER POLAND SP Z O OISSN: 0004-069XFrequency: 1 issue/year

ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, published by DE GRUYTER POLAND SP Z O O, stands as a pivotal journal in the field of immunology, contributing significantly to the advancement of knowledge and therapy in this crucial area of medicine since its inception in 1954. With an ISSN of 0004-069X and an E-ISSN of 1661-4917, the journal operates out of Switzerland, catering to an international audience of researchers, practitioners, and students. As reflected in its Scopus rankings, the journal is positioned within the third quartile in both Immunology and Allergy (Q3) and holds a commendable second quartile in Medicine (miscellaneous) (Q2), indicating its respectable influence within the academic community. The journal publishes original research, reviews, and clinical studies, offering a platform for exploring cutting-edge developments in immunological therapies and experimental methods. Although not currently an open-access journal, it continues to thrive as a valuable resource, reflecting a commitment to disseminating high-quality research and fostering academic discourse in the field. Researchers and professionals alike will find ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS an essential reference source for the latest advancements in immunological research and clinical applications.

IMMUNOBIOLOGY

Fostering collaboration for impactful discoveries in immunobiology.
Publisher: ELSEVIER GMBHISSN: 0171-2985Frequency: 12 issues/year

IMMUNOBIOLOGY is a prestigious academic journal published by Elsevier GmbH that significantly contributes to the fields of hematology and immunology. With its ISSN 0171-2985 and E-ISSN 1878-3279, this journal has been disseminating impactful research since 1979, positioning itself at the forefront of immunological and hematological advances. The journal holds a commendable ranking of Q2 in Hematology and Q3 in both Immunology and Immunology and Allergy, indicating its relevance and influence within the scientific community, as reflected by its Scopus rankings. Although IMMUNOBIOLOGY operates under a subscription model, it remains dedicated to expanding knowledge across disciplines, fostering innovative research, and facilitating connections among researchers, professionals, and students. Situated in Munich, Germany, this journal is continually evolving and aims to remain an essential resource for the latest discoveries and insights in the realms of immunity and blood disorders, ultimately enhancing our understanding of complex biological systems.

GENES AND IMMUNITY

Pioneering Insights into Genetic Influences on Immunity
Publisher: SPRINGERNATUREISSN: 1466-4879Frequency: 8 issues/year

GENES AND IMMUNITY, published by SpringerNature, is a leading scholarly journal dedicated to advancing the field of genetics and immunology. With an impressive impact factor and a distinguished ranking in the Q1 quartile of both Genetics and Immunology disciplines for 2023, this journal serves as a pivotal platform for researchers and professionals looking to explore the intricate relationships between genetic factors and immune responses. Established in 1999 and continuously published until 2024, it features high-quality peer-reviewed research articles, reviews, and commentary that address critical issues and recent advancements in the field. The journal adheres to rigorous academic standards, evidenced by its strong Scopus rankings, making it a valuable resource for students, researchers, and practitioners alike who are seeking to deepen their understanding of genetics' role in immunity. For those looking to keep abreast of cutting-edge insights, GENES AND IMMUNITY is an essential read.

CANCER CELL

Transforming Knowledge into Breakthrough Therapies
Publisher: CELL PRESSISSN: 1535-6108Frequency: 12 issues/year

Cancer Cell, published by Cell Press, represents a pinnacle of research in the fields of cancer research, cell biology, and oncology. With an impressive Impact Factor and ranking as Q1 in prestigious categories for both 2023 and previous years, this journal stands out as a vital resource for professionals and scholars dedicated to understanding the molecular underpinnings of cancer. Operating from Cambridge, MA, Cancer Cell has been an essential platform for innovative studies since its inception in 2002. Although it is not an Open Access journal, its rigorous peer-review process ensures that only the highest quality research is disseminated to the scientific community. Readers can expect to find a wealth of knowledge ranging from cutting-edge therapies to insights into tumor biology, thereby contributing significantly to the advancement of oncology. With rankings placing it among the top echelons of related fields—#2 in Cancer Research and #6 in Oncology—Cancer Cell is an indispensable reference for anyone committed to the fight against cancer.

IMMUNOLOGIC RESEARCH

Connecting Researchers to the Heart of Immunology
Publisher: SPRINGERISSN: 0257-277XFrequency: 6 issues/year

IMUNOLOGIC RESEARCH, published by Springer, is a prestigious journal dedicated to advancing the field of immunology. Since its inception in 1986, this journal has provided a vital platform for researchers, practitioners, and students to share groundbreaking studies and innovative findings that influence clinical and laboratory practices in immunology. With an impact factor that reflects its importance, being ranked in the Q2 category for the year 2023 and positioned at 98th out of 236 in Scopus rankings for Immunology, it is recognized among its peers for the quality of its publications. The journal emphasizes rigorous peer review and encourages submissions across a diverse range of topics including but not limited to immune responses, vaccine development, and disease mechanisms. Though it does not currently offer open access, its insightful articles remain crucial for professionals seeking to stay at the forefront of immunological research. Designed for a broad audience within the scientific community, IMMUNOLOGIC RESEARCH continues to foster discovery and discussion that shapes our understanding of immune function and its implications for health and disease.